USFDA inspections to be less disruptive for Indian pharma sector: Report
Indian pharma companies have increasingly de-risked their operations by slowly and steadily increasing sales to non-US markets, says India Ratings and Research.
usfda
January 2023
November 2022
October 2021
January 2021
January 2020
September 2019
September 2018
Cipla's Goa plant classified as 'Official Action Indicated' by USFDA; stock falls
USFDA may continue to withhold product approvals from this facility till the outstanding observations are resolved, says Cipla.
This pharma stock hits fresh all-time high; surges 135% in a year
This smallcap stock has more than doubled investors’ money in 12 months, rising from its 52-week low of ₹197.50 to an all-time high of ₹461.95 in intraday trade on the BSE.
Quality issues remain for Indian pharma companies: USFDA
The problems faced by FDA’s investigators in India are similar to those around the world, US Food and Drug Administration spokesperson Jeremy Kahn tells Fortune India.
Vaccines: The road to an emergency nod
Three firms have applied for emergency use authorisation in India as of now. AIIMS’ Amit Dinda, who is a part of the Global Coalition for Regulatory Science Research, explains the regulatory nuances.
Learnings from the Indian pharma industry
The difference between industry-leading firms and the rest is the unrelenting focus of the leading ones on brand creation, production and supply chain processes, and product innovation.
The toughest period is behind us: Vinita Gupta
India’s third-largest generic drugmaker Lupin is focussing on building a pipeline of specialty drugs, while cutting costs and addressing regulatory concerns.
India-U.S. are natural synergistic partners: Kiran MazumdarShaw
Biocon CMD Kiran Mazumdar Shaw speaks to Fortune India on the sidelines of the USIBC India Ideas Summit; says U.S. and India are natural synergistic partners.
